Ovarian Cancer

Trial to evaluate phenoxodiol as chemosensitizing agent

Published in Women's Health Weekly, May 20th, 2004

Marshall Edwards, Inc., (MSHL) has commenced a multicenter, multinational clinical trial that will study the ability of the investigational anticancer drug, phenoxodiol, to restore the sensitivity of ovarian cancer to the standard chemotherapies, paclitaxel and cisplatin.

The first site to enroll patients for this study is Yale-New Haven Hospital, New Haven, Connecticut. The second enrollment site will be announced in June 2004.

Laboratory studies have shown that phenoxodiol has the ability to restore sensitivity to standard chemotherapies in ovarian cancer cells that have been obtained from women whose tumors had previously become resistant to those...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2004-05-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry